Ingo Hartung

Ingo V. Hartung is a synthetic organic chemist by training (PhD University of Hannover/Germany, Postdoc Stanford University/US) with 20+ years of Pharma industry experience (Schering AG, Bayer AG, Merck KGaA). He has been project leader in oncology drug discovery and has had portfolio responsibility for preclinical research in the areas of epigenetics and immuno-oncology. Ingo is heading Merck’s global Medicinal Chemistry & Drug Design department which is driving drug discovery projects in oncology & immunology covering various types of small molecule modalities (inhibitors, degraders, antibody-drug conjugates). His research interests comprise all aspects of innovation in small molecule drug discovery. He is the author of >50 scientific publications and patents and board of director member of the Israeli Biotech company TenAces Biosciences.